Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-110513
Filing Date
2021-08-27
Accepted
2021-08-27 16:06:12
Documents
2
Period of Report
2021-08-26

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2125954-13_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2125954-13_3seq1.xml 3 1642
2 EXHIBIT 24.1 tm2125954d13_ex24-1.htm EX-24.1 8094
  Complete submission text file 0001104659-21-110513.txt   11226
Mailing Address 2525 EAST NORTH CAROLINA HIGHWAY 54 DURHAM NC 27713
Business Address 2525 EAST NORTH CAROLINA HIGHWAY 54 DURHAM NC 27713 919-313-9633
Humacyte, Inc. (Issuer) CIK: 0001818382 (see all company filings)

EIN.: 851763759 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 620 WADE AVENUE UNIT 501 RALEIGH NC 27605
Business Address
Scheessele William John (Reporting) CIK: 0001879378 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39532 | Film No.: 211218929